Boehringer Ingelheim Upgrades to Massively Scalable innovoPOINT® 6.6 for Enterprise Scalable Clinical and Investigator Portal Solution

Boehringer Ingelheim Upgrades to Massively Scalable innovoPOINT® 6.6 for Enterprise Scalable Clinical and Investigator Portal Solution

August 20, 2015 09:00 AM Eastern Daylight Time

IRVINE, Calif.--()--Boehringer Ingelheim, one of the world's leading biopharmaceutical companies, is now launching use of innovoPOINT® 6.6 by InnovoCommerce to enable the entire enterprise to streamline and digitize study start up, conduct and the close out processes. Boehringer Ingelheim selected the innovoPOINT solution in 2011 as part of the Cornerstone initiative—a visionary clinical infrastructure and systems modernization program. The company had the foresight to anticipate the need for one digital solution to represent a central interface for all of the company's clinical investigator and contract research partner organizations. After a careful review and diligence of the market, the innovoPOINT solution was identified as the most advanced and fit for the purpose of a clinical and investigator portal product.

As an integral foundation of Cornerstone, the company developed and executed a multi-phase digital clinical collaboration strategy. The multi-phased approach started with the implementation of secure document exchange and safety report distribution powered by innovoPOINT. Thereafter as part of the 6.6 release, new functionality included eTMF integration as well as future releases for standardized site training as well as modules for onboarding of new investigational sites.

Dr. Mark Hopley, Head of Central Clinical Operations, outlines that innovoPOINT enables Boehringer Ingelheim for a significant paradigm shift in its Clinical Trial Operations processes. Formerly decentralized, paper-based processes are now offered to our investigators on a unified, electronic platform. Retrieval and exchange of study documentation and many more site collaboration elements are now electronically surfaced and globally available to our investigator community. With that, we are making an important step to further improve our attractiveness as clinical research partner.

Veeps Piravi, Chief Strategy Officer of InnovoCommerce, emphasized that "it has been a true long-term, strategic partnership working with Boehringer Ingelheim. Both parties bring unique and complementary set of characteristics and capabilities to drive considerable value for company stakeholders—employees, investigators and clinical research partners."

The innovoPOINT 6.6 solution has been built specifically to effectively and efficiently manage massive document distribution scenarios associated with large scale clinical sponsors. With innovoPOINT 6.6, an individual clinical sponsor can now digitally manage hundreds of clinical trials, tens of thousands of users, and millions of documents. With the innovoPOINT 6.6 relational distribution engine, an enormous amount of complexity managing clinical trials collaboration is now streamlined and managed by the software. innovoPOINT 6.6 is hosted by Boehringer Ingelheim; however, the solution can be accessed via dedicated hosting, private cloud and public cloud options. InnovoCommerce provides GXP validation services for all deployments.

About InnovoCommerce LLC

InnovoCommerce is the world's leading company dedicated to secure, cloud-based clinical and investigator portal solutions. The company's eClinical collaboration suite includes the market's leading clinical and investigator portal product, study management and safety distribution systems. InnovoCommerce helps companies manage and control their clinical information value chain from site qualification through study close-out. All InnovoCommerce solutions can be installed on premise or utilized via a flexible, secure and FDA compliant private cloud-based offering. Integration with leading public cloud document storage vendors is also available. Learn more about InnovoCommerce by visiting


InnovoCommerce LLC
Daniel O'Connor, Chief Business Officer
Phone: 714-338-7149
Fax: 949-242-2194
[email protected]